Evidence map›Paper›PMID 26052530›Full record

ArticleMolecular therapy. Methods & clinical development2015

High-throughput monitoring of integration site clonality in preclinical and clinical gene therapy studies.

Frank A Giordano, Jens-Uwe Appelt, Barbara Link, Sebastian Gerdes, Christina Lehrer, Simone Scholz, Anna Paruzynski, Ingo Roeder, Frederik Wenz, Hanno Glimm and 4 more

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.2field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Gene therapy · 2025
    Article
  2. Mapping Hematopoietic Fate after Transplantation.Stem cell reviews and reports · 2025
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Frank A GiordanoDepartment of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University , Mannheim, Germany.
Jens-Uwe AppeltDepartment of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center (DKFZ) , Heidelberg, Germany ; CLC bio , Aarhus, Denmark.
Barbara LinkDepartment of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center (DKFZ) , Heidelberg, Germany.
Sebastian GerdesInstitute for Medical Informatics and Biometry, Faculty of Medicine Carl Gustav Carus, Technische Universität , Dresden, Germany.
Christina LehrerDepartment of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center (DKFZ) , Heidelberg, Germany.
Simone ScholzDepartment of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center (DKFZ) , Heidelberg, Germany.
Anna ParuzynskiDepartment of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center (DKFZ) , Heidelberg, Germany.
Ingo RoederInstitute for Medical Informatics and Biometry, Faculty of Medicine Carl Gustav Carus, Technische Universität , Dresden, Germany.
Frederik WenzDepartment of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University , Mannheim, Germany.
Hanno GlimmDepartment of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center (DKFZ) , Heidelberg, Germany.
Christof von KalleDepartment of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center (DKFZ) , Heidelberg, Germany.
Manuel GrezInstitute for Biomedical Research, Georg-Speyer-Haus , Frankfurt, Germany.
Manfred SchmidtDepartment of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center (DKFZ) , Heidelberg, Germany.
Stephanie LaufsDepartment of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center (DKFZ) , Heidelberg, Germany.
Heidelberg University · DENational Center for Tumor Diseases · DEGerman Cancer Research Center · DEUniversity Hospital Carl Gustav Carus · DEGeorg Speyer Haus · DEUniversity Hospital Heidelberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene transfer to hematopoietic stem cells with integrating vectors not only allows sustained correction of monogenic diseases but also tracking of individual clones in vivo. Quantitative real-time PCR (qPCR) has been shown to be an accurate method to quantify individual stem cell clones, yet due to frequently limited amounts of target material (especially in clinical studies), it is not useful for large-scale analyses. To explore whether vector integration site (IS) recovery techniques may be suitable to describe clonal contributions if combined with next-generation sequencing techniques, we designed artificial ISs of different sizes which were mixed to simulate defined clonal situations in clinical settings. We subjected all mixes to either linear amplification-mediated PCR (LAM-PCR) or nonrestrictive LAM-PCR (nrLAM-PCR), both combined with 454 sequencing. We showed that nrLAM-PCR/454-detected clonality allows estimating qPCR-detected clonality in vitro. We then followed the kinetics of two clones detected in a patient enrolled in a clinical gene therapy trial using both, nrLAM-PCR/454 and qPCR and also saw nrLAM-PCR/454 to correlate to qPCR-measured clonal contributions. The method presented here displays a feasible high-throughput strategy to monitor clonality in clinical gene therapy trials is at hand.

Identifiers

PMID26052530
PMCPMC4449016
OpenAlexW2335355929

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.